Repro-Med clears FDA warning letter, shuffles C-suite

Repro-Med Systems (OTC:REPR) said last week that the FDA cleared a 2016 warning letter for its Freedom 60 syringe infusion pump and Freedom Edge infusion pump and made some changes in the executive suite.

Repro-Med, which does business as RMS Medical Products, said the closure of the warning letter stemmed from its successful bid for 510(k) clearance for its Integrated Catch-Up Freedom Syringe Driver System, granted in September.

Get the full story on our sister site, Drug Delivery Business News.

The post Repro-Med clears FDA warning letter, shuffles C-suite appeared first on MassDevice.

from MassDevice http://ift.tt/2zH35Qd